Loading…

Diabetes and kidney dysfunction markedly alter the content of sphingolipids carried by circulating lipoproteins

•Assessing sphingolipid distribution in plasma lipoproteins is clinically valuable.•Plasma levels do not consistently reflect changes in circulating lipoproteins.•HDL sphingolipids are significantly lower in diabetes than in controls.•LDL sphingomyelins are higher in patients with diabetes and macro...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical lipidology 2022-03, Vol.16 (2), p.173-183
Main Authors: Hammad, Samar M, Hunt, Kelly J, Baker, Nathaniel L, Klein, Richard L, Lopes-Virella, Maria F
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c400t-890a9ae4baa1d5ad24eec6752ca197c6cae5da4b6432fb208b18b2945160767f3
cites cdi_FETCH-LOGICAL-c400t-890a9ae4baa1d5ad24eec6752ca197c6cae5da4b6432fb208b18b2945160767f3
container_end_page 183
container_issue 2
container_start_page 173
container_title Journal of clinical lipidology
container_volume 16
creator Hammad, Samar M
Hunt, Kelly J
Baker, Nathaniel L
Klein, Richard L
Lopes-Virella, Maria F
description •Assessing sphingolipid distribution in plasma lipoproteins is clinically valuable.•Plasma levels do not consistently reflect changes in circulating lipoproteins.•HDL sphingolipids are significantly lower in diabetes than in controls.•LDL sphingomyelins are higher in patients with diabetes and macroalbuminuria. We have previously shown that very long ceramides/lactosylceramides predicted the development of macroalbuminuria (MA) in type 1 diabetes and expanded our studies into type 2 diabetes. This study proposes comparing the levels of plasma sphingolipids and their distribution in circulating lipoproteins (VLDL/IDL, LDL, HDL2 and HDL3) between a healthy control group and two groups of subjects with type 2 diabetes, one with and other without MA. Plasma and lipoprotein sphingolipids/glycosphingolipids were measured using HPLC-MS/MS in 114 subjects (40 controls; 74 type 2 diabetes, 40 without MA; and 34 with MA) and the levels were compared between controls and the two groups of diabetes. Group effect sizes were calculated using Cohen's d. Sphingomyelin species carried by LDL are significantly higher in diabetic patients with MA than in those with normal albumin excretion rate (AER). Compared to controls, significant decreases in the levels of sphingolipids carried by HDL in patients with diabetes with normal AER or MA were observed for all sphingolipid classes except for hexosylceramide, which was normal in diabetic patients without MA. Although lower than in controls, the levels of lactosylceramides carried by HDL2/HDL3 were significantly higher in diabetes with MA. Considering the critical role sphingolipids play in major cell biological responses and cell signaling pathways, the consequences for disease development of changes in the distribution of sphingolipids/glycosphingolipids carried by lipoproteins could be considerable. Our work is just a first step to address a considerable gap in our present knowledge in this important field.
doi_str_mv 10.1016/j.jacl.2021.12.004
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2628298510</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1933287421003512</els_id><sourcerecordid>2628298510</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-890a9ae4baa1d5ad24eec6752ca197c6cae5da4b6432fb208b18b2945160767f3</originalsourceid><addsrcrecordid>eNp9kE9v1DAQxS1ERf_AF-CAfOSSYDt24khcUFsKUqVe4GxN7An1NmsvtoOUb1-vtnDkNCPNe2_0foS856zljPefdu0O7NIKJnjLRcuYfEUuuB76Rg56fF33sesaoQd5Ti5z3jGm1MDUG3LeKS71qMUFiTceJiyYKQRHn7wLuFG35XkNtvgY6B7SE7plo7AUTLQ8IrUxFAyFxpnmw6MPv-LiD95laiElj45OG7U-2XWBUq-0XuMhxYI-5LfkbIYl47uXeUV-fr39cf2tuX-4-3795b6xkrHS6JHBCCgnAO4UOCERbT8oYYGPg-0toHIgp152Yp4E0xPXkxil4j0b-mHursjHU259_HvFXMzeZ4vLAgHjmo3ohRajVpxVqThJbYo5J5zNIflaezOcmSNoszNH0OYI2nBhKuhq-vCSv057dP8sf8lWweeTAGvLPx6TydZjsOh8QluMi_5_-c_155Gf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2628298510</pqid></control><display><type>article</type><title>Diabetes and kidney dysfunction markedly alter the content of sphingolipids carried by circulating lipoproteins</title><source>Elsevier</source><creator>Hammad, Samar M ; Hunt, Kelly J ; Baker, Nathaniel L ; Klein, Richard L ; Lopes-Virella, Maria F</creator><creatorcontrib>Hammad, Samar M ; Hunt, Kelly J ; Baker, Nathaniel L ; Klein, Richard L ; Lopes-Virella, Maria F</creatorcontrib><description>•Assessing sphingolipid distribution in plasma lipoproteins is clinically valuable.•Plasma levels do not consistently reflect changes in circulating lipoproteins.•HDL sphingolipids are significantly lower in diabetes than in controls.•LDL sphingomyelins are higher in patients with diabetes and macroalbuminuria. We have previously shown that very long ceramides/lactosylceramides predicted the development of macroalbuminuria (MA) in type 1 diabetes and expanded our studies into type 2 diabetes. This study proposes comparing the levels of plasma sphingolipids and their distribution in circulating lipoproteins (VLDL/IDL, LDL, HDL2 and HDL3) between a healthy control group and two groups of subjects with type 2 diabetes, one with and other without MA. Plasma and lipoprotein sphingolipids/glycosphingolipids were measured using HPLC-MS/MS in 114 subjects (40 controls; 74 type 2 diabetes, 40 without MA; and 34 with MA) and the levels were compared between controls and the two groups of diabetes. Group effect sizes were calculated using Cohen's d. Sphingomyelin species carried by LDL are significantly higher in diabetic patients with MA than in those with normal albumin excretion rate (AER). Compared to controls, significant decreases in the levels of sphingolipids carried by HDL in patients with diabetes with normal AER or MA were observed for all sphingolipid classes except for hexosylceramide, which was normal in diabetic patients without MA. Although lower than in controls, the levels of lactosylceramides carried by HDL2/HDL3 were significantly higher in diabetes with MA. Considering the critical role sphingolipids play in major cell biological responses and cell signaling pathways, the consequences for disease development of changes in the distribution of sphingolipids/glycosphingolipids carried by lipoproteins could be considerable. Our work is just a first step to address a considerable gap in our present knowledge in this important field.</description><identifier>ISSN: 1933-2874</identifier><identifier>EISSN: 1876-4789</identifier><identifier>DOI: 10.1016/j.jacl.2021.12.004</identifier><identifier>PMID: 35148982</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Albuminuria ; Ceramide ; Diabetes Mellitus, Type 2 ; Dihydrosphingosine ; Glycosphingolipid ; Hexosylceramide ; Humans ; Kidney ; Lactosylceramide ; Lactosylceramides ; Lipoproteins ; Lipoproteins, LDL ; Macroalbuminuria ; Sphingolipid ; Sphingolipids - metabolism ; Sphingomyelin ; Sphingosine ; Tandem Mass Spectrometry ; Type 2 diabetes</subject><ispartof>Journal of clinical lipidology, 2022-03, Vol.16 (2), p.173-183</ispartof><rights>2022</rights><rights>Copyright © 2022. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-890a9ae4baa1d5ad24eec6752ca197c6cae5da4b6432fb208b18b2945160767f3</citedby><cites>FETCH-LOGICAL-c400t-890a9ae4baa1d5ad24eec6752ca197c6cae5da4b6432fb208b18b2945160767f3</cites><orcidid>0000-0001-5572-1700</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35148982$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hammad, Samar M</creatorcontrib><creatorcontrib>Hunt, Kelly J</creatorcontrib><creatorcontrib>Baker, Nathaniel L</creatorcontrib><creatorcontrib>Klein, Richard L</creatorcontrib><creatorcontrib>Lopes-Virella, Maria F</creatorcontrib><title>Diabetes and kidney dysfunction markedly alter the content of sphingolipids carried by circulating lipoproteins</title><title>Journal of clinical lipidology</title><addtitle>J Clin Lipidol</addtitle><description>•Assessing sphingolipid distribution in plasma lipoproteins is clinically valuable.•Plasma levels do not consistently reflect changes in circulating lipoproteins.•HDL sphingolipids are significantly lower in diabetes than in controls.•LDL sphingomyelins are higher in patients with diabetes and macroalbuminuria. We have previously shown that very long ceramides/lactosylceramides predicted the development of macroalbuminuria (MA) in type 1 diabetes and expanded our studies into type 2 diabetes. This study proposes comparing the levels of plasma sphingolipids and their distribution in circulating lipoproteins (VLDL/IDL, LDL, HDL2 and HDL3) between a healthy control group and two groups of subjects with type 2 diabetes, one with and other without MA. Plasma and lipoprotein sphingolipids/glycosphingolipids were measured using HPLC-MS/MS in 114 subjects (40 controls; 74 type 2 diabetes, 40 without MA; and 34 with MA) and the levels were compared between controls and the two groups of diabetes. Group effect sizes were calculated using Cohen's d. Sphingomyelin species carried by LDL are significantly higher in diabetic patients with MA than in those with normal albumin excretion rate (AER). Compared to controls, significant decreases in the levels of sphingolipids carried by HDL in patients with diabetes with normal AER or MA were observed for all sphingolipid classes except for hexosylceramide, which was normal in diabetic patients without MA. Although lower than in controls, the levels of lactosylceramides carried by HDL2/HDL3 were significantly higher in diabetes with MA. Considering the critical role sphingolipids play in major cell biological responses and cell signaling pathways, the consequences for disease development of changes in the distribution of sphingolipids/glycosphingolipids carried by lipoproteins could be considerable. Our work is just a first step to address a considerable gap in our present knowledge in this important field.</description><subject>Albuminuria</subject><subject>Ceramide</subject><subject>Diabetes Mellitus, Type 2</subject><subject>Dihydrosphingosine</subject><subject>Glycosphingolipid</subject><subject>Hexosylceramide</subject><subject>Humans</subject><subject>Kidney</subject><subject>Lactosylceramide</subject><subject>Lactosylceramides</subject><subject>Lipoproteins</subject><subject>Lipoproteins, LDL</subject><subject>Macroalbuminuria</subject><subject>Sphingolipid</subject><subject>Sphingolipids - metabolism</subject><subject>Sphingomyelin</subject><subject>Sphingosine</subject><subject>Tandem Mass Spectrometry</subject><subject>Type 2 diabetes</subject><issn>1933-2874</issn><issn>1876-4789</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kE9v1DAQxS1ERf_AF-CAfOSSYDt24khcUFsKUqVe4GxN7An1NmsvtoOUb1-vtnDkNCPNe2_0foS856zljPefdu0O7NIKJnjLRcuYfEUuuB76Rg56fF33sesaoQd5Ti5z3jGm1MDUG3LeKS71qMUFiTceJiyYKQRHn7wLuFG35XkNtvgY6B7SE7plo7AUTLQ8IrUxFAyFxpnmw6MPv-LiD95laiElj45OG7U-2XWBUq-0XuMhxYI-5LfkbIYl47uXeUV-fr39cf2tuX-4-3795b6xkrHS6JHBCCgnAO4UOCERbT8oYYGPg-0toHIgp152Yp4E0xPXkxil4j0b-mHursjHU259_HvFXMzeZ4vLAgHjmo3ohRajVpxVqThJbYo5J5zNIflaezOcmSNoszNH0OYI2nBhKuhq-vCSv057dP8sf8lWweeTAGvLPx6TydZjsOh8QluMi_5_-c_155Gf</recordid><startdate>202203</startdate><enddate>202203</enddate><creator>Hammad, Samar M</creator><creator>Hunt, Kelly J</creator><creator>Baker, Nathaniel L</creator><creator>Klein, Richard L</creator><creator>Lopes-Virella, Maria F</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5572-1700</orcidid></search><sort><creationdate>202203</creationdate><title>Diabetes and kidney dysfunction markedly alter the content of sphingolipids carried by circulating lipoproteins</title><author>Hammad, Samar M ; Hunt, Kelly J ; Baker, Nathaniel L ; Klein, Richard L ; Lopes-Virella, Maria F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-890a9ae4baa1d5ad24eec6752ca197c6cae5da4b6432fb208b18b2945160767f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Albuminuria</topic><topic>Ceramide</topic><topic>Diabetes Mellitus, Type 2</topic><topic>Dihydrosphingosine</topic><topic>Glycosphingolipid</topic><topic>Hexosylceramide</topic><topic>Humans</topic><topic>Kidney</topic><topic>Lactosylceramide</topic><topic>Lactosylceramides</topic><topic>Lipoproteins</topic><topic>Lipoproteins, LDL</topic><topic>Macroalbuminuria</topic><topic>Sphingolipid</topic><topic>Sphingolipids - metabolism</topic><topic>Sphingomyelin</topic><topic>Sphingosine</topic><topic>Tandem Mass Spectrometry</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hammad, Samar M</creatorcontrib><creatorcontrib>Hunt, Kelly J</creatorcontrib><creatorcontrib>Baker, Nathaniel L</creatorcontrib><creatorcontrib>Klein, Richard L</creatorcontrib><creatorcontrib>Lopes-Virella, Maria F</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical lipidology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hammad, Samar M</au><au>Hunt, Kelly J</au><au>Baker, Nathaniel L</au><au>Klein, Richard L</au><au>Lopes-Virella, Maria F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diabetes and kidney dysfunction markedly alter the content of sphingolipids carried by circulating lipoproteins</atitle><jtitle>Journal of clinical lipidology</jtitle><addtitle>J Clin Lipidol</addtitle><date>2022-03</date><risdate>2022</risdate><volume>16</volume><issue>2</issue><spage>173</spage><epage>183</epage><pages>173-183</pages><issn>1933-2874</issn><eissn>1876-4789</eissn><abstract>•Assessing sphingolipid distribution in plasma lipoproteins is clinically valuable.•Plasma levels do not consistently reflect changes in circulating lipoproteins.•HDL sphingolipids are significantly lower in diabetes than in controls.•LDL sphingomyelins are higher in patients with diabetes and macroalbuminuria. We have previously shown that very long ceramides/lactosylceramides predicted the development of macroalbuminuria (MA) in type 1 diabetes and expanded our studies into type 2 diabetes. This study proposes comparing the levels of plasma sphingolipids and their distribution in circulating lipoproteins (VLDL/IDL, LDL, HDL2 and HDL3) between a healthy control group and two groups of subjects with type 2 diabetes, one with and other without MA. Plasma and lipoprotein sphingolipids/glycosphingolipids were measured using HPLC-MS/MS in 114 subjects (40 controls; 74 type 2 diabetes, 40 without MA; and 34 with MA) and the levels were compared between controls and the two groups of diabetes. Group effect sizes were calculated using Cohen's d. Sphingomyelin species carried by LDL are significantly higher in diabetic patients with MA than in those with normal albumin excretion rate (AER). Compared to controls, significant decreases in the levels of sphingolipids carried by HDL in patients with diabetes with normal AER or MA were observed for all sphingolipid classes except for hexosylceramide, which was normal in diabetic patients without MA. Although lower than in controls, the levels of lactosylceramides carried by HDL2/HDL3 were significantly higher in diabetes with MA. Considering the critical role sphingolipids play in major cell biological responses and cell signaling pathways, the consequences for disease development of changes in the distribution of sphingolipids/glycosphingolipids carried by lipoproteins could be considerable. Our work is just a first step to address a considerable gap in our present knowledge in this important field.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35148982</pmid><doi>10.1016/j.jacl.2021.12.004</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-5572-1700</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1933-2874
ispartof Journal of clinical lipidology, 2022-03, Vol.16 (2), p.173-183
issn 1933-2874
1876-4789
language eng
recordid cdi_proquest_miscellaneous_2628298510
source Elsevier
subjects Albuminuria
Ceramide
Diabetes Mellitus, Type 2
Dihydrosphingosine
Glycosphingolipid
Hexosylceramide
Humans
Kidney
Lactosylceramide
Lactosylceramides
Lipoproteins
Lipoproteins, LDL
Macroalbuminuria
Sphingolipid
Sphingolipids - metabolism
Sphingomyelin
Sphingosine
Tandem Mass Spectrometry
Type 2 diabetes
title Diabetes and kidney dysfunction markedly alter the content of sphingolipids carried by circulating lipoproteins
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T19%3A42%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diabetes%20and%20kidney%20dysfunction%20markedly%20alter%20the%20content%20of%20sphingolipids%20carried%20by%20circulating%20lipoproteins&rft.jtitle=Journal%20of%20clinical%20lipidology&rft.au=Hammad,%20Samar%20M&rft.date=2022-03&rft.volume=16&rft.issue=2&rft.spage=173&rft.epage=183&rft.pages=173-183&rft.issn=1933-2874&rft.eissn=1876-4789&rft_id=info:doi/10.1016/j.jacl.2021.12.004&rft_dat=%3Cproquest_cross%3E2628298510%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c400t-890a9ae4baa1d5ad24eec6752ca197c6cae5da4b6432fb208b18b2945160767f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2628298510&rft_id=info:pmid/35148982&rfr_iscdi=true